Oral small-molecule tyrosine kinase inhibitors (TKIs) targeting ROS1 fusion oncoproteins have revolutionized treatment paradigms for metastatic ROS1-positive NSCLC, significantly improving patient prognosis. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.